Rhythm Pharmaceuticals, Inc.
(NASDAQ : RYTM)

( )
RYTM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.40%282.621.5%$846.35m
MRNAModerna, Inc. -0.58%175.380.0%$764.29m
GILDGilead Sciences, Inc. -1.22%85.211.0%$712.21m
REGNRegeneron Pharmaceuticals, Inc. 0.71%741.482.6%$477.59m
VRTXVertex Pharmaceuticals, Inc. 0.74%315.301.9%$412.70m
BIIBBiogen, Inc. -4.34%291.901.8%$344.20m
ILMNIllumina, Inc. -0.95%216.913.2%$252.36m
SNSSSunesis Pharmaceuticals, Inc. -9.35%2.520.7%$176.16m
BNTXBioNTech SE 4.29%161.490.0%$168.04m
BMRNBioMarin Pharmaceutical, Inc. 1.80%98.664.2%$153.96m
AXSMAxsome Therapeutics, Inc. 31.54%74.741.6%$145.83m
MRTXMirati Therapeutics, Inc. -2.99%95.671.6%$134.05m
TECHBio-Techne Corp. -2.53%330.404.5%$124.21m
NVAXNovavax, Inc. 0.61%16.6475.3%$71.50m
HALOHalozyme Therapeutics, Inc. 3.29%56.4718.4%$70.68m

Company Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.